Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 31Squamous Cell Carcinoma of Head and Neck 21Carcinoma, Non-Small-Cell Lung 20Neoplasms 18Breast Neoplasms 18Glioblastoma 17Esophageal Squamous Cell Carcinoma 16Rectal Neoplasms 15Lung Neoplasms 15Esophageal Neoplasms 15Head and Neck Neoplasms 12Uterine Cervical Neoplasms 11Neoplasm Metastasis 10Glioma 10Nasopharyngeal Carcinoma 8Stomach Neoplasms 7Radiation Injuries 7Oropharyngeal Neoplasms 7Brain Neoplasms 7Hyperthermia 6Carcinoma, Hepatocellular 6Astrocytoma 6Urinary Bladder Neoplasms 5Small Cell Lung Carcinoma 5Sarcoma 5Oligodendroglioma 5Colorectal Neoplasms 5Carcinoma, Renal Cell 5Triple Negative Breast Neoplasms 4Pancreatic Neoplasms 4

Interventions

cemiplimab 1Taxes 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy 1Radiation 1Platinum 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Cisplatin 1Chemoradiotherapy 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Sinonasal Squamous Cell Carcinoma × Radiotherapy × Clear all
NCT07281417 2026-05-22

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

National Cancer Institute (NCI)

Phase 2 Recruiting
108 enrolled

Sinonasal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡